DR5-targeting tetrameric nanobody agonist TAS266

{
  "id": "MLC-T-ONC-013168",
  "term": "DR5-targeting tetrameric nanobody agonist TAS266",
  "field": "Oncology and biomedicine",
  "definition": "An agonistic tetravalent nanobody, in which the four single, high affinity heavy chain variable domain (VHH) antibodies are separated by a peptide linker, targeting death receptor type 5 (DR5), with potential antineoplastic activity. Upon administration, DR5-targeting tetrameric nanobody agonist TAS266, with its four DR5-specific single-chain antibodies, specifically binds to and activates DR5 receptors. This results in the activation of caspase cascades and induction of apoptosis in DR5-expressing tumor cells. DR5, a cell surface receptor and member of the tumor necrosis factor (TNF)-receptor superfamily, triggers apoptosis. Compared to certain anti-DR5 antibody agonists, TAS266 shows increased receptor activation.",
  "synonyms": [
    "tetrameric nanobody agonist-targeting death receptor 5 TAS266"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/dr5-targeting-tetrameric-nanobody-agonist-tas266/"
}